Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
The FDA recently finalized four new final Guidance for Industry documents for cancer clinical trial eligibility criteria that describe ways that clinical trials can safely include patients who have historically been excluded.
ASCO and the Association of Community Cancer Centers (ACCC) announced a new collaboration to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer.
The ASCO Research Community Forum offers free resources and tools to connect the research community and support the conduct of clinical trials at research sites.
The ASCO Research Community Forum and Cancer Research Committee conducted a survey to gain insights into the types of changes and challenges that oncology research programs are experiencing since the COVID-19 outbreak and how sites are adapting their research program in response. Learn more from the press release.
The ASCO Research Community Forum offers free resources to support the conduct and management of clinical trials.
ASCO conducted a survey to gain insights into the types of changes and challenges that oncology research programs are experiencing since the COVID-19 outbreak and how sites are adapting their research program in response. View the manuscript (DOI: 10.1200/ OP.20.00275) and accompanying report online.